dr. reckamp on mk-2206 for the treatment of egfr wild-type nsclc
Published 9 years ago • 202 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
2:24
dr. reckamp on met-targeting strategies in nsclc
-
2:14
reckamp immunotherapy for previously treated patients with nsclc
-
0:49
dr. reckamp on molecular testing in lung cancer
-
0:32
dr. reckamp discusses the use of hsp90 inhibitors
-
1:36
dr. reckamp on cabozantinib plus erlotinib for advanced egfr-mutant nsclc
-
1:13
dr. reckamp on pivotal data in metex14-altered nsclc
-
1:11
dr. reckamp on targeted therapy options for rare mutations in nsclc
-
0:59
dr. karen reckamp evaluates the predictive efficacy of the veristrat in nsclc
-
5:04
gefitinib: inhibitor of egfr tyrosine kinase mutants in nsclc
-
5:20
immuno-oncology agents for mm: checkpoint inhibitors and nk-cells
-
4:09
the pathophysiology of non-small cell lung cancer
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
16:22
debate: drug of choice for exon 19 del egfr mutant nsclc - afatinib
-
24:07
part 4 - optimal management of egfr m nsclc patients - dr. shyam agarwal, delhi
-
0:58
dr. papadimitrakopoulou on treatment options for egfr-mutant nsclc
-
12:58
egfr inhibitor therapy in second line
-
2:20
dr. kris on the relay trial in egfr nsclc
-
1:26
first line treatment of egfr mutation-positive nsclc
-
4:39
treatment for egfr nsclc
-
2:01
checkmate-722: investigating the addition of immunotherapy to chemotherapy in egfr-mutant nsclc
-
13:26
debate: drug of choice for exon 19 del egfr mutant nsclc - any egfr tki
-
1:10
gracecastuc-070_lung_dr. reckamp on "which patients do you test for molecular marker, and for what?"